US FDA approves Roche's oral treatment for early-stage breast cancer
The US Food and Drug Administration approved Roche's oral treatment for certain patients with estrogen receptor-positive, HER2-negative early-stage breast cancer.
The US Food and Drug Administration approved Roche's oral treatment for certain patients with estrogen receptor-positive, HER2-negative early-stage breast cancer.
The US Food and Drug Administration approved Roche's oral treatment for certain patients with estrogen receptor-positive, HER2-negative early-stage breast cancer.